A5042456607- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Medical Imaging Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Cancer Cells and Metastasis
- Esophageal Cancer Research and Treatment
- Colorectal and Anal Carcinomas
- Meningioma and schwannoma management
- Neurofibromatosis and Schwannoma Cases
- Global Cancer Incidence and Screening
- Linguistics and Discourse Analysis
- Patient-Provider Communication in Healthcare
- Gastric Cancer Management and Outcomes
- Cervical Cancer and HPV Research
- Lymphoma Diagnosis and Treatment
- Linguistic and Sociocultural Studies
- Ovarian cancer diagnosis and treatment
- Pituitary Gland Disorders and Treatments
- Empathy and Medical Education
- Ferroptosis and cancer prognosis
- Endometrial and Cervical Cancer Treatments
Witten/Herdecke University
2024
Klinikum Dortmund
2020-2024
Neoadjuvant chemotherapy is standard of care in human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC), irrespective the hormone status. Trastuzumab-emtansine (T-DM1), antibody-drug conjugate, highly effective HER2+ EBC; however, no survival data are available for de-escalated conjugate-based neoadjuvant therapy without conventional chemotherapy.In WSG-ADAPT-TP (ClinicalTrials.gov identifier: NCT01779206) phase II trial, 375 centrally reviewed patients with...
Prognostic or predictive biomarkers in HER2-positive early breast cancer (EBC) may inform treatment optimization. The ADAPT HER2-positive/hormone receptor-positive phase II trial (NCT01779206) demonstrated pathological complete response (pCR) rates of ~40% following de-escalated with 12 weeks neoadjuvant ado-trastuzumab emtansine (T-DM1) ± endocrine therapy. In this exploratory analysis, we evaluated potential predictors to effects PIK3CA mutations and immune (CD8 PD-L1) apoptotic markers...
Abstract Background Prior research has shown that around 5%–7% of patients in breast cancer centers Germany participate the discussion their own case within a multidisciplinary tumor conference (MTC). The PINTU study is one first to this practice. objective describe (a) how patient participation MTCs implemented, (b) what role patients, and (c) experience MTCs. Methods six gynecological North Rhine‐Westphalia, Germany, with without participation, are studied prospectively by...
590 Background: pCR successfully identified candidates for (chemotherapy) de-escalation in the ADAPT HER2+ trial program. Here, we report biomarker analysis single arm, hypothesis-generating Keyriched-1 (NCT03988036) HER2-E eBC treated with pembrolizumab and dual HER2 blockade. The rationale is based on high efficacy of anti-HER2 agents potentially immunogenicity immune checkpoint protein expression eBC. Methods: 48 patients 2+ (ISH+) or 3+ (stage I-III) subtype received (200 mg),...
In nearly half of sporadic low grade meningiomas no chromosome aberration can be detected. the majority other 22 is lost. higher this loss followed by characteristic secondary aberrations. Regarding molecular findings in Schwannomas, homozygous or mutation NF2 gene located on 22, was supposed also to primary event meningioma development. However, all high but only a minority protein observed. Therefore, both hypothetical combined heterozygous inactivation two more tumour suppressor genes (at...
Abstract Purpose: To identify associations of biological signatures and stromal tumor-infiltrating lymphocytes (sTIL) with pathological complete response (pCR; ypT0 ypN0) survival in the Phase II WSG-ADAPT HER2+/HR− trial (NCT01817452). Experimental Design: Patients cT1-cT4c, cN0–3 early breast cancer (EBC) were randomized to pertuzumab+trastuzumab (P+T, n = 92) or P+T+paclitaxel (n 42). Gene expression analyzed baseline biopsies using NanoString Breast Cancer 360 panel 117); on-treatment...
Abstract Purpose: Only limited data are available on predictive markers for use of chemotherapy-free, anti-HER2 combinations in HER2-positive early breast cancer (eBC), particular within the molecularly distinct HER2+/HR- subgroup. Background: In ADAPT trial, a promising pCR about 43-45% was found patients treated by 4 cycles pertuzumab and trastuzumab with either defined response (low tumor cellularity or relative Ki-67 decrease ≥30%) indeterminate (e.g. no visible ultrasound), compared to...
<h3>Introduction/Background</h3> Immature ovarian teratomas are rare germ cell tumors mostly diagnosed in young women. They associated with a variable potential of distant metastasis. According to current guidelines, recommended treatment is complete tumor resection, operative staging including peritoneal washing, omentectomy, biopsies followed by postoperative chemotherapy- except stage I. <h3>Methodology</h3> A 29- year- old woman was referred our department three months after left-sided...
Abstract Background: Among patients with highly heterogeneous HER2+ breast cancer (BC), pathological complete response (pCR) (ypT0/is/ypN0) is associated improved prognosis. The prospective, phase-II neoadjuvant 3-arm WSG HER2+/HR+ trial (ADAPT-TP) showed pCR rates of about 41.0% after 4xT-DM1+/-ET and 15% trastuzumab+ET. Pre-planned translational analysis ADAPT-TP has revealed several biomarkers impact on pCR, such as PIK3CA mutation status, HER2-enriched subtype (by PAM50), Bcl-2 most...
Abstract Background In unselected HER2+ early breast cancer (EBC), de-escalated chemotherapy-free neoadjuvant therapy (NAT) with dual HER2-blockade induces pCR rates of only 20%-40%. order to achieve by comparable those achieved chemotherapy-based regimens, patient selection and more effective regimens are thus key. KEYRICHED-1 (NCT03988036), a single-arm phase 2 study, is the first trial investigate NAT HER2 blockade pembrolizumab in HER2-enriched EBC. translational subproject, we analyzed...
<p>CONSORT diagram</p>
<div>AbstractPurpose:<p>To identify associations of biological signatures and stromal tumor-infiltrating lymphocytes (sTIL) with pathological complete response (pCR; ypT0 ypN0) survival in the Phase II WSG-ADAPT HER2<sup>+</sup>/HR<sup>−</sup> trial (NCT01817452).</p>Experimental Design:<p>Patients cT1-cT4c, cN0–3 early breast cancer (EBC) were randomized to pertuzumab+trastuzumab (P+T, <i>n</i> = 92) or P+T+paclitaxel...
<p>Supplementary Figure 2 shows association between RNA signatures and ypT0/is ypN0</p>
<p>Supplementary Figure 3 shows association between RNA signatures and overall survival</p>